Morgan Stanley Trims Radius Health (RDUS) Target Price to $59.00

Radius Health (NASDAQ:RDUS) had its target price reduced by Morgan Stanley from $61.00 to $59.00 in a research report released on Friday morning. They currently have an overweight rating on the biopharmaceutical company’s stock.

RDUS has been the topic of several other research reports. BidaskClub upgraded Radius Health from a strong sell rating to a sell rating in a report on Wednesday, December 27th. Citigroup reiterated a hold rating and issued a $43.00 price objective on shares of Radius Health in a report on Monday, January 22nd. JPMorgan Chase & Co. decreased their price objective on Radius Health from $70.00 to $60.00 and set an overweight rating on the stock in a report on Monday, February 12th. Zacks Investment Research upgraded Radius Health from a sell rating to a hold rating in a report on Monday, January 8th. Finally, Cantor Fitzgerald reiterated a buy rating and issued a $58.00 price objective on shares of Radius Health in a report on Thursday, January 18th. One research analyst has rated the stock with a sell rating, six have given a hold rating and six have issued a buy rating to the company. The stock currently has a consensus rating of Hold and a consensus target price of $52.00.

How to Become a New Pot Stock Millionaire

Radius Health (NASDAQ:RDUS) traded down $0.03 on Friday, hitting $33.80. The stock had a trading volume of 521,685 shares, compared to its average volume of 1,062,031. The stock has a market capitalization of $1,524.94, a P/E ratio of -5.83 and a beta of 1.19. The company has a debt-to-equity ratio of 0.69, a quick ratio of 4.96 and a current ratio of 5.04. Radius Health has a 1 year low of $24.66 and a 1 year high of $49.16.

Radius Health (NASDAQ:RDUS) last released its quarterly earnings data on Thursday, March 1st. The biopharmaceutical company reported ($1.59) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.43) by ($0.16). The firm had revenue of $7.66 million during the quarter, compared to analysts’ expectations of $7.37 million. The company’s revenue for the quarter was up 666.0% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.22) EPS. analysts expect that Radius Health will post -5.05 earnings per share for the current year.

In other news, major shareholder Growth N. V. Biotech acquired 80,000 shares of the business’s stock in a transaction on Friday, March 2nd. The shares were acquired at an average cost of $32.52 per share, with a total value of $2,601,600.00. Following the transaction, the insider now owns 5,853,799 shares in the company, valued at approximately $190,365,543.48. The acquisition was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Growth N. V. Biotech acquired 75,000 shares of the business’s stock in a transaction on Friday, February 9th. The shares were purchased at an average cost of $34.38 per share, for a total transaction of $2,578,500.00. Following the completion of the transaction, the insider now owns 5,773,799 shares in the company, valued at approximately $198,503,209.62. The disclosure for this purchase can be found here. 15.00% of the stock is owned by insiders.

A number of institutional investors have recently bought and sold shares of the business. MetLife Investment Advisors LLC bought a new stake in Radius Health during the 4th quarter valued at approximately $558,000. Endurant Capital Management LP boosted its position in Radius Health by 294.3% during the 4th quarter. Endurant Capital Management LP now owns 41,400 shares of the biopharmaceutical company’s stock valued at $1,315,000 after acquiring an additional 30,900 shares in the last quarter. Jane Street Group LLC boosted its position in Radius Health by 24.7% during the 4th quarter. Jane Street Group LLC now owns 10,043 shares of the biopharmaceutical company’s stock valued at $319,000 after acquiring an additional 1,988 shares in the last quarter. Crestline Management LP bought a new stake in Radius Health during the 4th quarter valued at approximately $2,181,000. Finally, Raymond James & Associates boosted its position in Radius Health by 44.5% during the 4th quarter. Raymond James & Associates now owns 15,224 shares of the biopharmaceutical company’s stock valued at $484,000 after acquiring an additional 4,692 shares in the last quarter.

WARNING: This piece of content was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of US and international copyright law. The correct version of this piece of content can be viewed at https://www.tickerreport.com/banking-finance/3296364/morgan-stanley-trims-radius-health-rdus-target-price-to-59-00.html.

About Radius Health

Radius Health, Inc is a biopharmaceutical company. The Company is focused on the developing therapeutics in the areas of osteoporosis, oncology and endocrine diseases. The Company’s lead investigational product candidate, TYMLOS (abaloparatide-SC) injection is developed for the treatment of postmenopausal women with osteoporosis at high risk for fracture.

Analyst Recommendations for Radius Health (NASDAQ:RDUS)

Receive News & Ratings for Radius Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Radius Health and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Reviewing Carbo Ceramics  & Owens Corning
Reviewing Carbo Ceramics & Owens Corning
Analyzing NextEra Energy Partners  and Its Peers
Analyzing NextEra Energy Partners and Its Peers
E.ON  versus Its Competitors Head-To-Head Survey
E.ON versus Its Competitors Head-To-Head Survey
Brokerages Anticipate Enterprise Financial Services Co.  to Post $0.86 Earnings Per Share
Brokerages Anticipate Enterprise Financial Services Co. to Post $0.86 Earnings Per Share
MKS Instruments  Stock Price Down 9.4%
MKS Instruments Stock Price Down 9.4%
Gold Fields  Shares Gap Up to $3.92
Gold Fields Shares Gap Up to $3.92


© 2006-2018 Ticker Report. Google+.